-DOCSTART- -X- O
PURPOSE -X- _ O
OF -X- _ O
REVIEW -X- _ O
: -X- _ O
To -X- _ O
summarize -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
adjuvants -X- _ B-Intervention
in -X- _ O
eliciting -X- _ O
desirable -X- _ O
antibody -X- _ O
responses -X- _ O
against -X- _ O
HIV-1 -X- _ B-Patient
with -X- _ O
particular -X- _ O
emphasis -X- _ O
on -X- _ O
both -X- _ O
historical -X- _ O
context -X- _ O
and -X- _ O
recent -X- _ O
developments. -X- _ O
RECENT -X- _ O
FINDINGS -X- _ O
: -X- _ O
Increased -X- _ O
understanding -X- _ O
of -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
pattern -X- _ O
recognition -X- _ O
receptors -X- _ O
such -X- _ O
as -X- _ O
Toll-like -X- _ O
receptors -X- _ O
in -X- _ O
recruiting -X- _ O
and -X- _ O
directing -X- _ O
the -X- _ O
immune -X- _ O
system -X- _ O
has -X- _ O
increased -X- _ O
the -X- _ O
variety -X- _ O
of -X- _ O
adjuvant -X- _ B-Outcome
formulations -X- _ I-Outcome
being -X- _ I-Outcome
tested -X- _ I-Outcome
in -X- _ I-Outcome
animal -X- _ I-Outcome
models -X- _ I-Outcome
and -X- _ I-Outcome
humans. -X- _ I-Outcome
Across -X- _ I-Outcome
all -X- _ I-Outcome
vaccine -X- _ I-Outcome
platforms -X- _ I-Outcome
, -X- _ I-Outcome
adjuvant -X- _ I-Outcome
formulations -X- _ I-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ I-Outcome
enhance -X- _ I-Outcome
desirable -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
higher -X- _ I-Outcome
antibody -X- _ I-Outcome
titers -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
functional -X- _ I-Outcome
activity. -X- _ I-Outcome
Although -X- _ O
no -X- _ O
vaccine -X- _ O
formulation -X- _ O
has -X- _ O
yet -X- _ O
succeeded -X- _ O
in -X- _ O
eliciting -X- _ O
broad -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
against -X- _ O
HIV-1 -X- _ O
, -X- _ O
the -X- _ B-Outcome
ability -X- _ I-Outcome
of -X- _ I-Outcome
adjuvants -X- _ I-Outcome
to -X- _ I-Outcome
direct -X- _ I-Outcome
the -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
to -X- _ I-Outcome
immunogens -X- _ I-Outcome
suggests -X- _ I-Outcome
they -X- _ I-Outcome
will -X- _ I-Outcome
be -X- _ I-Outcome
critically -X- _ I-Outcome
important -X- _ I-Outcome
in -X- _ I-Outcome
any -X- _ I-Outcome
successful -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
vaccine. -X- _ I-Outcome
SUMMARY -X- _ O
: -X- _ O
The -X- _ O
parallel -X- _ O
development -X- _ O
of -X- _ O
adjuvants -X- _ O
along -X- _ O
with -X- _ O
better -X- _ O
HIV-1 -X- _ O
immunogens -X- _ O
will -X- _ O
be -X- _ O
needed -X- _ O
for -X- _ O
a -X- _ O
successful -X- _ O
AIDS -X- _ O
vaccine. -X- _ O
Additional -X- _ O
comparative -X- _ O
testing -X- _ O
will -X- _ O
be -X- _ O
required -X- _ O
to -X- _ O
determine -X- _ O
the -X- _ O
optimal -X- _ O
adjuvant -X- _ O
and -X- _ O
immunogen -X- _ O
regimen -X- _ O
that -X- _ O
can -X- _ O
elicit -X- _ O
antibody -X- _ O
responses -X- _ O
capable -X- _ O
of -X- _ O
blocking -X- _ O
HIV-1 -X- _ O
transmission -X- _ O
. -X- _ O

